<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459890</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Understanding the Omicron Variant Impact in Healthcare Workers: Insights from the Prospective COVID-19 Post-Immunization Serological Cohort in Munich (KoCo-Impf) on Risk Factors for Breakthrough and Reinfections.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1556</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101556</ELocationID><Abstract><AbstractText>This study analyzes immune responses to SARS-CoV-2 vaccination and infection, including asymptomatic cases, focusing on infection risks during the Omicron wave, particularly among high-risk healthcare workers. In the KoCo-Impf study, we monitored 6088 vaccinated participants in Munich aged 18 and above. From 13 May to 31 July 2022, 2351 participants were follow-uped. Logistic regression models evaluated primary, secondary, and breakthrough infections (BTIs). Roche Elecsys<sup>®</sup> Anti-SARS-CoV-2 assays detected prior infections (via anti-Nucleocapsid antibodies) and assessed vaccination/infection impact (via anti-Spike antibodies) using dried blood spots. Our findings revealed an anti-Nucleocapsid seroprevalence of 44.1%. BTIs occurred in 38.8% of participants, with reinfections in 48.0%. Follow-up participation was inversely associated with current smoking and non-vaccination, while significantly increasing with age and receipt of three vaccine doses. Larger household sizes and younger age increased infection risks, whereas multiple vaccinations and older age reduced them. Household size and specific institutional subgroups were risk factors for BTIs. The anti-Nucleocapsid value prior to the second infection was significantly associated with reinfection risk. Institutional subgroups influenced all models, underscoring the importance of tailored outbreak responses. The KoCo-Impf study underscores the importance of vaccination, demographic factors, and institutional settings in understanding SARS-CoV-2 infection risks during the Omicron wave.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Janke</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9262-1597</Identifier><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubio-Acero</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weigert</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, 80539 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Center for Machine Learning (MCML), 80539 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinkemeyer</LastName><ForeName>Christina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0003-2749-8056</Identifier><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khazaei</LastName><ForeName>Yeganeh</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, 80539 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinlein</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, 80539 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Gleut</LastName><ForeName>Ronan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9429-9925</Identifier><AffiliationInfo><Affiliation>Institute of Computational Biology, Helmholtz Munich, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Core Facility Statistical Consulting, Helmholtz Munich, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radon</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, LMU University Hospital, LMU Munich, 80336 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for International Health (CIH), LMU University Hospital, LMU Munich, 80336 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Pneumology Center (CPC) Munich, German Center for Lung Research (DZL), 89337 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannes</LastName><ForeName>Marlene</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit Global Health, Helmholtz Zentrum München, German Research Centre for Environmental Health (HMGU), 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Picasso</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucke</LastName><ForeName>Anne Elisabeth</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plank</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotta</LastName><ForeName>Irene Charlotte</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paunovic</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhelyazkova</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8085-5003</Identifier><AffiliationInfo><Affiliation>Institut für Notfallmedizin und Medizinmanagement (INM), LMU Klinikum, LMU München, 80336 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noreña</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winter</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoelscher</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7642-1835</Identifier><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for International Health (CIH), LMU University Hospital, LMU Munich, 80336 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit Global Health, Helmholtz Zentrum München, German Research Centre for Environmental Health (HMGU), 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wieser</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max Von Pettenkofer Institute, Faculty of Medicine, LMU Munich, 80336 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Küchenhoff</LastName><ForeName>Helmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, 80539 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castelletti</LastName><ForeName>Noemi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Radiation Medicine, Helmholtz Zentrum München, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>On Behalf Of The Orchestra Working Group</LastName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Grant Agreement No. 101016167</GrantID><Agency>European Union</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName><SupplMeshName Type="Disease" UI="C000718127">COVID-19 breakthrough infections</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="Y">Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000084063" MajorTopicYN="Y">Reinfection</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093742" MajorTopicYN="N">Breakthrough Infections</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ORCHESTRA</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">breakthrough infections</Keyword><Keyword MajorTopicYN="N">health care workers</Keyword><Keyword MajorTopicYN="N">immunologic response</Keyword><Keyword MajorTopicYN="N">reinfections</Keyword><Keyword MajorTopicYN="N">seroprevalence</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>In addition to the funding disclosed in the funding section, AW and MH report personal fees and non-financial support from Roche Diagnostics, non-financial support from Euroimmun, non-financial support from Viramed, and non-financial support from Mikrogen. AW and MH report grants, non-financial support and other from German Centre for Infection Research DZIF, grants and non-financial support from Government of Bavaria, non-financial support from BMW, non-financial support from Munich Police, non-financial support and other from Accenture. MH and AW report personal fees and non-financial support received from Box-Betrobox and non-financial support from Becker MVZ during the conduction of this study. AW is involved in other different patents and companies, not in relation to the serology of SARS-CoV-2. AW reports personal fees and others from Haeraeus Sensors and non-financial support from Bruker Daltonics, all of which are outside the submitted work and non-related to SARS-CoV-2. The funders had no role in this study’s design, data collection, data analyses, data interpretation, writing, or submission of this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459890</ArticleId><ArticleId IdType="pmc">PMC11512372</ArticleId><ArticleId IdType="doi">10.3390/v16101556</ArticleId><ArticleId IdType="pii">v16101556</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lai C.-C., Shih T.-P., Ko W.-C., Tang H.-J., Hsueh P.-R. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease-2019 (COVID-19): The Epidemic and the Challenges. Int. J. Antimicrob. Agents. 2020;55:105924. doi: 10.1016/j.ijantimicag.2020.105924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105924</ArticleId><ArticleId IdType="pmc">PMC7127800</ArticleId><ArticleId IdType="pubmed">32081636</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Director-General’s Opening Remarks at the Media Briefing on COVID-19—11 March 2020.  [(accessed on 18 February 2024)].  Available online:  https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.</Citation></Reference><Reference><Citation>WHO  COVID-19 Dashboard Showing Total Cumulative Reported COVID-19 Cases and Reported COVID-19 Deaths.  [(accessed on 18 February 2024)].  Available online:  https://data.who.int/dashboards/covid19/cases.</Citation></Reference><Reference><Citation>Rothe C., Schunk M., Sothmann P., Bretzel G., Froeschl G., Wallrauch C., Zimmer T., Thiel V., Janke C., Guggemos W., et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N. Engl. J. Med. 2020;382:970–971. doi: 10.1056/NEJMc2001468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2001468</ArticleId><ArticleId IdType="pmc">PMC7120970</ArticleId><ArticleId IdType="pubmed">32003551</ArticleId></ArticleIdList></Reference><Reference><Citation>Soegiarto G., Mahdi B.A., Wulandari L., Fahmita K.D., Hadmoko S.T., Gautama H.I., Prasetyaningtyas D., Prasetyo M.E., Negoro P.P., Arafah N., et al. Evaluation of Antibody Response and Adverse Effects Following Heterologous COVID-19 Vaccine Booster with mRNA Vaccine among Healthcare Workers in Indonesia. Vaccines. 2023;11:1160. doi: 10.3390/vaccines11071160.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11071160</ArticleId><ArticleId IdType="pmc">PMC10386191</ArticleId><ArticleId IdType="pubmed">37514976</ArticleId></ArticleIdList></Reference><Reference><Citation>Doernberg S.B., Holubar M., Jain V., Weng Y., Lu D., Bollyky J.B., Sample H., Huang B., Craik C.S., Desai M., et al. Incidence and Prevalence of Coronavirus Disease 2019 Within a Healthcare Worker Cohort During the First Year of the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2022;75:1573–1584. doi: 10.1093/cid/ciac210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac210</ArticleId><ArticleId IdType="pmc">PMC8992269</ArticleId><ArticleId IdType="pubmed">35279023</ArticleId></ArticleIdList></Reference><Reference><Citation>Inghels M., Kane R., Lall P., Nelson D., Nanyonjo A., Asghar Z., Ward D., McCranor T., Kavanagh T., Hogue T., et al. Ethnicity and Risk for SARS-CoV-2 Infection among the Healthcare Workforce: Results of a Retrospective Cohort Study in Rural United Kingdom. Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 2022;122:115–122. doi: 10.1016/j.ijid.2022.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.05.013</ArticleId><ArticleId IdType="pmc">PMC9098657</ArticleId><ArticleId IdType="pubmed">35569751</ArticleId></ArticleIdList></Reference><Reference><Citation>Platten M., Nienhaus A., Peters C., Cranen R., Wisplinghoff H., Kersten J.F., Bach A.D., Michels G. Cumulative Incidence of SARS-CoV-2 in Healthcare Workers at a General Hospital in Germany during the Pandemic—A Longitudinal Analysis. Int. J. Environ. Res. Public Health. 2022;19:2429. doi: 10.3390/ijerph19042429.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19042429</ArticleId><ArticleId IdType="pmc">PMC8872027</ArticleId><ArticleId IdType="pubmed">35206616</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L.H., Drew D.A., Graham M.S., Joshi A.D., Guo C.-G., Ma W., Mehta R.S., Warner E.T., Sikavi D.R., Lo C.-H., et al. Risk of COVID-19 among Front-Line Health-Care Workers and the General Community: A Prospective Cohort Study. Lancet Public Health. 2020;5:e475–e483. doi: 10.1016/S2468-2667(20)30164-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30164-X</ArticleId><ArticleId IdType="pmc">PMC7491202</ArticleId><ArticleId IdType="pubmed">32745512</ArticleId></ArticleIdList></Reference><Reference><Citation>Iversen K., Bundgaard H., Hasselbalch R.B., Kristensen J.H., Nielsen P.B., Pries-Heje M., Knudsen A.D., Christensen C.E., Fogh K., Norsk J.B., et al. Risk of COVID-19 in Health-Care Workers in Denmark: An Observational Cohort Study. Lancet Infect. Dis. 2020;20:1401–1408. doi: 10.1016/S1473-3099(20)30589-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30589-2</ArticleId><ArticleId IdType="pmc">PMC7398038</ArticleId><ArticleId IdType="pubmed">32758438</ArticleId></ArticleIdList></Reference><Reference><Citation>Brophy J.T., Keith M.M., Hurley M., McArthur J.E. Sacrificed: Ontario Healthcare Workers in the Time of COVID-19. New Solut. J. Environ. Occup. Health Policy NS. 2021;30:267–281. doi: 10.1177/1048291120974358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1048291120974358</ArticleId><ArticleId IdType="pmc">PMC7804366</ArticleId><ArticleId IdType="pubmed">33174768</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez-Ochoa S.A., Franco O.H., Rojas L.Z., Raguindin P.F., Roa-Díaz Z.M., Wyssmann B.M., Guevara S.L.R., Echeverría L.E., Glisic M., Muka T. COVID-19 in Health-Care Workers: A Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical Characteristics, and Outcomes. Am. J. Epidemiol. 2021;190:161–175. doi: 10.1093/aje/kwaa191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwaa191</ArticleId><ArticleId IdType="pmc">PMC7499478</ArticleId><ArticleId IdType="pubmed">32870978</ArticleId></ArticleIdList></Reference><Reference><Citation>Brehm T.T., Schwinge D., Lampalzer S., Schlicker V., Küchen J., Thompson M., Ullrich F., Huber S., Schmiedel S., Addo M.M., et al. Seroprevalence of SARS-CoV-2 Antibodies among Hospital Workers in a German Tertiary Care Center: A Sequential Follow-up Study. Int. J. Hyg. Environ. Health. 2021;232:113671. doi: 10.1016/j.ijheh.2020.113671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijheh.2020.113671</ArticleId><ArticleId IdType="pmc">PMC7832715</ArticleId><ArticleId IdType="pubmed">33338782</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinkemeyer C., Khazaei Y., Weigert M., Hannes M., Le Gleut R., Plank M., Winter S., Noreña I., Meier T., Xu L., et al. The Prospective COVID-19 Post-Immunization Serological Cohort in Munich (KoCo-Impf): Risk Factors and Determinants of Immune Response in Healthcare Workers. Viruses. 2023;15:1574. doi: 10.3390/v15071574.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15071574</ArticleId><ArticleId IdType="pmc">PMC10383736</ArticleId><ArticleId IdType="pubmed">37515259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabetian G., Moghadami M., Hashemizadeh Fard Haghighi L., Shahriarirad R., Fallahi M.J., Asmarian N., Moeini Y.S. COVID-19 Infection among Healthcare Workers: A Cross-Sectional Study in Southwest Iran. Virol. J. 2021;18:58. doi: 10.1186/s12985-021-01532-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-021-01532-0</ArticleId><ArticleId IdType="pmc">PMC7968574</ArticleId><ArticleId IdType="pubmed">33731169</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross J.V., Mohren J., Erren T.C. COVID-19 and Healthcare Workers: A Rapid Systematic Review into Risks and Preventive Measures. BMJ Open. 2021;11:e042270. doi: 10.1136/bmjopen-2020-042270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-042270</ArticleId><ArticleId IdType="pmc">PMC7818819</ArticleId><ArticleId IdType="pubmed">33472783</ArticleId></ArticleIdList></Reference><Reference><Citation>Gholami M., Fawad I., Shadan S., Rowaiee R., Ghanem H., Hassan Khamis A., Ho S.B. COVID-19 and Healthcare Workers: A Systematic Review and Meta-Analysis. Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 2021;104:335–346. doi: 10.1016/j.ijid.2021.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.01.013</ArticleId><ArticleId IdType="pmc">PMC7798435</ArticleId><ArticleId IdType="pubmed">33444754</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath J., McAloon C.G., More S.J., Garrett S., Reidy C., Geary U., Noonan N., Bergin C. Risk Factors for SARS-CoV-2 Infection in Healthcare Workers Following an Identified Nosocomial COVID-19 Exposure during Waves 1-3 of the Pandemic in Ireland. Epidemiol. Infect. 2022;150:e186. doi: 10.1017/S0950268822001595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268822001595</ArticleId><ArticleId IdType="pmc">PMC9744455</ArticleId><ArticleId IdType="pubmed">36372066</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gleut R., Plank M., Pütz P., Radon K., Bakuli A., Rubio-Acero R., Paunovic I., Rieß F., Winter S., Reinkemeyer C., et al. The Representative COVID-19 Cohort Munich (KoCo19): From the Beginning of the Pandemic to the Delta Virus Variant. BMC Infect. Dis. 2023;23:466. doi: 10.1186/s12879-023-08435-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08435-1</ArticleId><ArticleId IdType="pmc">PMC10339498</ArticleId><ArticleId IdType="pubmed">37442952</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., Abdullahi A., Ferreira I.A.T.M., Goonawardane N., Saito A., Kimura I., Yamasoba D., Gerber P.P., Fatihi S., Rathore S., et al. Altered TMPRSS2 Usage by SARS-CoV-2 Omicron Impacts Infectivity and Fusogenicity. Nature. 2022;603:706–714. doi: 10.1038/s41586-022-04474-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04474-x</ArticleId><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett B.J., Grove J., MacLean O.A., Wilkie C., De Lorenzo G., Furnon W., Cantoni D., Scott S., Logan N., Ashraf S., et al. SARS-CoV-2 Omicron Is an Immune Escape Variant with an Altered Cell Entry Pathway. Nat. Microbiol. 2022;7:1161–1179. doi: 10.1038/s41564-022-01143-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01143-7</ArticleId><ArticleId IdType="pmc">PMC9352574</ArticleId><ArticleId IdType="pubmed">35798890</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha L.B., Foster C., Rawlinson W., Tedla N., Bull R.A. Evolution of the SARS-CoV-2 Omicron Variants BA.1 to BA.5: Implications for Immune Escape and Transmission. Rev. Med. Virol. 2022;32:e2381. doi: 10.1002/rmv.2381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2381</ArticleId><ArticleId IdType="pmc">PMC9349777</ArticleId><ArticleId IdType="pubmed">35856385</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang W., Kang L., Cao G., Wang Y., Gao P., Liu J., Liu M. Percentage of Asymptomatic Infections among SARS-CoV-2 Omicron Variant-Positive Individuals: A Systematic Review and Meta-Analysis. Vaccines. 2022;10:1049. doi: 10.3390/vaccines10071049.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10071049</ArticleId><ArticleId IdType="pmc">PMC9321237</ArticleId><ArticleId IdType="pubmed">35891214</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio-Acero R., Castelletti N., Fingerle V., Olbrich L., Bakuli A., Wölfel R., Girl P., Müller K., Jochum S., Strobl M., et al. In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-Characterized Oligo-/Asymptomatic Patients. Infect. Dis. Ther. 2021;10:1505–1518. doi: 10.1007/s40121-021-00475-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00475-x</ArticleId><ArticleId IdType="pmc">PMC8208377</ArticleId><ArticleId IdType="pubmed">34137000</ArticleId></ArticleIdList></Reference><Reference><Citation>Olbrich L., Castelletti N., Schälte Y., Garí M., Pütz P., Bakuli A., Pritsch M., Kroidl I., Saathoff E., Guggenbuehl Noller J.M., et al. Head-to-Head Evaluation of Seven Different Seroassays Including Direct Viral Neutralisation in a Representative Cohort for SARS-CoV-2. J. Gen. Virol. 2021;102:001653. doi: 10.1099/jgv.0.001653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001653</ArticleId><ArticleId IdType="pmc">PMC8604188</ArticleId><ArticleId IdType="pubmed">34623233</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyerl J., Rubio-Acero R., Castelletti N., Paunovic I., Kroidl I., Khan Z.N., Bakuli A., Tautz A., Oft J., Hoelscher M., et al. A Dried Blood Spot Protocol for High Throughput Analysis of SARS-CoV-2 Serology Based on the Roche Elecsys Anti-N Assay. EBioMedicine. 2021;70:103502. doi: 10.1016/j.ebiom.2021.103502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103502</ArticleId><ArticleId IdType="pmc">PMC8320407</ArticleId><ArticleId IdType="pubmed">34333234</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelletti N., Paunovic I., Rubio-Acero R., Beyerl J., Plank M., Reinkemeyer C., Kroidl I., Noreña I., Winter S., Olbrich L., et al. A Dried Blood Spot Protocol for High-Throughput Quantitative Analysis of SARS-CoV-2 RBD Serology Based on the Roche Elecsys System. Microbiol. Spectr. 2024;12:e02885-23. doi: 10.1128/spectrum.02885-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.02885-23</ArticleId><ArticleId IdType="pmc">PMC10986497</ArticleId><ArticleId IdType="pubmed">38426747</ArticleId></ArticleIdList></Reference><Reference><Citation>Moons K.G.M., Donders R.A.R.T., Stijnen T., Harrell F.E. Using the Outcome for Imputation of Missing Predictor Values Was Preferred. J. Clin. Epidemiol. 2006;59:1092–1101. doi: 10.1016/j.jclinepi.2006.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2006.01.009</ArticleId><ArticleId IdType="pubmed">16980150</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin D.B. Multiple Imputation for Nonresponse in Surveys. Volume 81 John Wiley &amp; Sons; Hoboken, NJ, USA: 2004.</Citation></Reference><Reference><Citation>Wood S.N. Generalized Additive Models: An Introduction with R. Chapman and Hall/CRC; New York, NY, USA: 2017.</Citation></Reference><Reference><Citation>Bauer A., Weigert M., Jalal H. APCtools: Descriptive and Model-Based Age-Period-CohortAnalysis. J. Open Source Softw. 2022;7:4056. doi: 10.21105/joss.04056.</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.04056</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalakrishnan V., Pethe S., Kefayati S., Srinivasan R., Hake P., Deshpande A., Liu X., Hoang E., Davila M., Bianco S., et al. Globally Local: Hyper-Local Modeling for Accurate Forecast of COVID-19. Epidemics. 2021;37:100510. doi: 10.1016/j.epidem.2021.100510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.epidem.2021.100510</ArticleId><ArticleId IdType="pmc">PMC8518202</ArticleId><ArticleId IdType="pubmed">34688165</ArticleId></ArticleIdList></Reference><Reference><Citation>Collatuzzo G., Visci G., Violante F.S., Porru S., Spiteri G., Monaco M.G.L., Larese Fillon F., Negro C., Janke C., Castelletti N., et al. Determinants of Anti-S Immune Response at 6 Months after COVID-19 Vaccination in a Multicentric European Cohort of Healthcare Workers—ORCHESTRA Project. Front. Immunol. 2022;13:986085. doi: 10.3389/fimmu.2022.986085.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.986085</ArticleId><ArticleId IdType="pmc">PMC9559243</ArticleId><ArticleId IdType="pubmed">36248889</ArticleId></ArticleIdList></Reference><Reference><Citation>Collatuzzo G., Lodi V., Feola D., De Palma G., Sansone E., Sala E., Janke C., Castelletti N., Porru S., Spiteri G., et al. Determinants of Anti-S Immune Response at 9 Months after COVID-19 Vaccination in a Multicentric European Cohort of Healthcare Workers-ORCHESTRA Project. Viruses. 2022;14:2657. doi: 10.3390/v14122657.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122657</ArticleId><ArticleId IdType="pmc">PMC9781450</ArticleId><ArticleId IdType="pubmed">36560660</ArticleId></ArticleIdList></Reference><Reference><Citation>Leomanni L., Collatuzzo G., Sansone E., Sala E., De Palma G., Porru S., Spiteri G., Monaco M.G.L., Basso D., Pavanello S., et al. Determinants of Anti-S Immune Response at 12 Months after SARS-CoV-2 Vaccination in a Multicentric European Cohort of Healthcare Workers—ORCHESTRA Project. Vaccines. 2023;11:1527. doi: 10.3390/vaccines11101527.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11101527</ArticleId><ArticleId IdType="pmc">PMC10610704</ArticleId><ArticleId IdType="pubmed">37896931</ArticleId></ArticleIdList></Reference><Reference><Citation>Radon K., Bakuli A., Pütz P., Le Gleut R., Guggenbuehl Noller J.M., Olbrich L., Saathoff E., Garí M., Schälte Y., Frahnow T., et al. From First to Second Wave: Follow-up of the Prospective COVID-19 Cohort (KoCo19) in Munich (Germany) BMC Infect. Dis. 2021;21:925. doi: 10.1186/s12879-021-06589-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06589-4</ArticleId><ArticleId IdType="pmc">PMC8423599</ArticleId><ArticleId IdType="pubmed">34493217</ArticleId></ArticleIdList></Reference><Reference><Citation>Garfin D.R., Fischhoff B., Holman E.A., Silver R.C. Risk Perceptions and Health Behaviors as COVID-19 Emerged in the United States: Results from a Probability-Based Nationally Representative Sample. J. Exp. Psychol. Appl. 2021;27:584–598. doi: 10.1037/xap0000374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/xap0000374</ArticleId><ArticleId IdType="pmc">PMC9707407</ArticleId><ArticleId IdType="pubmed">35073127</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipolletta S., Andreghetti G.R., Mioni G. Risk Perception towards COVID-19: A Systematic Review and Qualitative Synthesis. Int. J. Environ. Res. Public Health. 2022;19:4649. doi: 10.3390/ijerph19084649.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19084649</ArticleId><ArticleId IdType="pmc">PMC9028425</ArticleId><ArticleId IdType="pubmed">35457521</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprengholz P., Bruckmann R., Wiedermann M., Brockmann D., Betsch C. From Delta to Omicron: The Role of Individual Factors and Social Context in Self-Reported Compliance with Pandemic Regulations and Recommendations. Soc. Sci. Med. 1982. 2023;317:115633. doi: 10.1016/j.socscimed.2022.115633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2022.115633</ArticleId><ArticleId IdType="pmc">PMC9783191</ArticleId><ArticleId IdType="pubmed">36577223</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Yamamoto S., Oshiro Y., Inamura N., Nemoto T., Horii K., Takeuchi J.S., Mizoue T., Konishi M., Ozeki M., et al. Comparison of Risk Factors for SARS-CoV-2 Infection among Healthcare Workers during Omicron and Delta Dominance Periods in Japan. J. Hosp. Infect. 2023;134:97–107. doi: 10.1016/j.jhin.2023.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2023.01.018</ArticleId><ArticleId IdType="pmc">PMC9933573</ArticleId><ArticleId IdType="pubmed">36805085</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Wolff K.C., Slama N., Alexeeff S.E., Sakoda L.C., Fogelberg R., Myers L.C., Campbell C.I., Adams A.S., Prochaska J.J. Tobacco Smoking and Risk of SARS-CoV-2 Infection and Disease Severity Among Adults in an Integrated Healthcare System in California. Nicotine Tob. Res. Off. J. Soc. Res. Nicotine Tob. 2023;25:211–220. doi: 10.1093/ntr/ntac090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ntr/ntac090</ArticleId><ArticleId IdType="pmc">PMC9825324</ArticleId><ArticleId IdType="pubmed">35368066</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Wolff K.C., Slama N., Sakoda L.C., Prochaska J.J., Fogelberg R., Alexeeff S.E. Current Tobacco Smoking and Risk of SARS-CoV-2 Infection and Hospitalization: Evaluating the Role of Socio-Demographic Factors and Comorbidities. Prev. Med. 2023;172:107523. doi: 10.1016/j.ypmed.2023.107523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2023.107523</ArticleId><ArticleId IdType="pmc">PMC10131738</ArticleId><ArticleId IdType="pubmed">37116761</ArticleId></ArticleIdList></Reference><Reference><Citation>Paleiron N., Mayet A., Marbac V., Perisse A., Barazzutti H., Brocq F.-X., Janvier F., Dautzenberg B., Bylicki O. Impact of Tobacco Smoking on the Risk of COVID-19: A Large Scale Retrospective Cohort Study. Nicotine Tob. Res. Off. J. Soc. Res. Nicotine Tob. 2021;23:1398–1404. doi: 10.1093/ntr/ntab004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ntr/ntab004</ArticleId><ArticleId IdType="pmc">PMC7953961</ArticleId><ArticleId IdType="pubmed">33420786</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Zheng R., Liang R., Wu B., Wang C., Zhuo L., Wu M., Jie Y., Lin B., Chang L., et al. Effects of Smoking on ACE2 Expression Pattern: Risk and Severity of SARS-CoV-2 Infection. Clin. Lab. 2021;67 doi: 10.7754/Clin.Lab.2020.201124.</Citation><ArticleIdList><ArticleId IdType="doi">10.7754/Clin.Lab.2020.201124</ArticleId><ArticleId IdType="pubmed">34258966</ArticleId></ArticleIdList></Reference><Reference><Citation>Günther F., Einhauser S., Peterhoff D., Wiegrebe S., Niller H.H., Beileke S., Steininger P., Burkhardt R., Küchenhoff H., Gefeller O., et al. Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves—Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study. Int. J. Environ. Res. Public. Health. 2022;19:16996. doi: 10.3390/ijerph192416996.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph192416996</ArticleId><ArticleId IdType="pmc">PMC9779618</ArticleId><ArticleId IdType="pubmed">36554876</ArticleId></ArticleIdList></Reference><Reference><Citation>Wratil P.R., Le Thi T.G., Osterman A., Badell I., Huber M., Zhelyazkova A., Wichert S.P., Litwin A., Hörmansdorfer S., Strobl F., et al. Dietary Habits, Traveling and the Living Situation Potentially Influence the Susceptibility to SARS-CoV-2 Infection: Results from Healthcare Workers Participating in the RisCoin Study. Infection. 2024;52:1425–1437. doi: 10.1007/s15010-024-02201-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-024-02201-4</ArticleId><ArticleId IdType="pmc">PMC11289231</ArticleId><ArticleId IdType="pubmed">38436913</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra-Hebert A.D., Jehi L., Ji X., Nowacki A.S., Gordon S., Terpeluk P., Chung M.K., Mehra R., Dell K.M., Pennell N., et al. Impact of the COVID-19 Pandemic on Healthcare Workers’ Risk of Infection and Outcomes in a Large, Integrated Health System. J. Gen. Intern. Med. 2020;35:3293–3301. doi: 10.1007/s11606-020-06171-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-020-06171-9</ArticleId><ArticleId IdType="pmc">PMC7462108</ArticleId><ArticleId IdType="pubmed">32875500</ArticleId></ArticleIdList></Reference><Reference><Citation>Langlete P., Tesli M., Veneti L., Starrfelt J., Elstrøm P., Meijerink H. Estimated Vaccine Effectiveness against SARS-CoV-2 Delta and Omicron Infections among Health Care Workers and the General Adult Population in Norway, August 2021–January 2022. Vaccine. 2023;41:3923–3929. doi: 10.1016/j.vaccine.2023.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.05.022</ArticleId><ArticleId IdType="pmc">PMC10169571</ArticleId><ArticleId IdType="pubmed">37211454</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong S.-C., Chan V.W.-M., Yuen L.L.-H., AuYeung C.H.-Y., Leung J.O.-Y., Li C.-K., Kwok M.O.-T., So S.Y.-C., Chen J.H.-K., Chiu K.H.-Y., et al. Infection of Healthcare Workers despite a High Vaccination Rate during the Fifth Wave of COVID-19 Due to Omicron Variant in Hong Kong. Infect. Prev. Pract. 2023;5:100261. doi: 10.1016/j.infpip.2022.100261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.infpip.2022.100261</ArticleId><ArticleId IdType="pmc">PMC9705264</ArticleId><ArticleId IdType="pubmed">36465098</ArticleId></ArticleIdList></Reference><Reference><Citation>Cegolon L., Negro C., Mastrangelo G., Filon F.L., ORCHESTRA Working Group Primary SARS-CoV-2 Infections, Re-Infections and Vaccine Effectiveness during the Omicron Transmission Period in Healthcare Workers of Trieste and Gorizia (Northeast Italy), 1 December 2021–31 May 2022. Viruses. 2022;14:2688. doi: 10.3390/v14122688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122688</ArticleId><ArticleId IdType="pmc">PMC9784665</ArticleId><ArticleId IdType="pubmed">36560692</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., Cromer D., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., Subbarao K., Kent S.J., Triccas J.A., Davenport M.P. Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic SARS-CoV-2 Infection. Nat. Med. 2021;27:1205–1211. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Atti A., Insalata F., Carr E.J., Otter A.D., Castillo-Olivares J., Wu M., Harvey R., Howell M., Chan A., Lyall J., et al. Antibody Correlates of Protection from SARS-CoV-2 Reinfection Prior to Vaccination: A Nested Case-Control within the SIREN Study. J. Infect. 2022;85:545–556. doi: 10.1016/j.jinf.2022.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.09.004</ArticleId><ArticleId IdType="pmc">PMC9458758</ArticleId><ArticleId IdType="pubmed">36089104</ArticleId></ArticleIdList></Reference><Reference><Citation>Porru S., Monaco M.G.L., Spiteri G., Carta A., Caliskan G., Violán C., Torán-Monserrat P., Vimercati L., Tafuri S., Boffetta P., et al. Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA Project. J. Epidemiol. Glob. Health. 2023;13:577–588. doi: 10.1007/s44197-023-00139-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44197-023-00139-8</ArticleId><ArticleId IdType="pmc">PMC10468456</ArticleId><ArticleId IdType="pubmed">37480426</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Forecasting Team Past SARS-CoV-2 Infection Protection against Re-Infection: A Systematic Review and Meta-Analysis. Lancet Lond. Engl. 2023;401:833–842. doi: 10.1016/S0140-6736(22)02465-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02465-5</ArticleId><ArticleId IdType="pmc">PMC9998097</ArticleId><ArticleId IdType="pubmed">36930674</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowell A.C., Waiblinger D., Wright J., Ladhani S.N., Moss P., sKIDS Investigation Team Nucleocapsid-Specific Antibodies as a Correlate of Protection against SARS-CoV-2 Reinfection in Children. J. Infect. 2023;87:267–269. doi: 10.1016/j.jinf.2023.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.06.018</ArticleId><ArticleId IdType="pmc">PMC10303317</ArticleId><ArticleId IdType="pubmed">37391077</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra M., Tian R., Zhang C., Clarence E., Sacher C.S., Miranda J.N., De La Fuente J.R.O., Mathew M., Green D., Patel S., et al. Role of IgG against N-Protein of SARS-CoV2 in COVID19 Clinical Outcomes. Sci. Rep. 2021;11:3455. doi: 10.1038/s41598-021-83108-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-83108-0</ArticleId><ArticleId IdType="pmc">PMC7875990</ArticleId><ArticleId IdType="pubmed">33568776</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B., Feng Y., Mo X., Zheng P., Wang Q., Li P., Peng P., Liu X., Chen Z., Huang H., et al. Kinetics of SARS-CoV-2 Specific IgM and IgG Responses in COVID-19 Patients. Emerg. Microbes Infect. 2020;9:940–948. doi: 10.1080/22221751.2020.1762515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1762515</ArticleId><ArticleId IdType="pmc">PMC7273175</ArticleId><ArticleId IdType="pubmed">32357808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroidl I., Winter S., Rubio-Acero R., Bakuli A., Geldmacher C., Eser T.M., Déak F., Horn S., Zielke A., Ahmed M.I.M., et al. Studying Temporal Titre Evolution of Commercial SARS-CoV-2 Assays Reveals Significant Shortcomings of Using BAU Standardization for Comparison. Virol. J. 2023;20:200. doi: 10.1186/s12985-023-02167-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-023-02167-z</ArticleId><ArticleId IdType="pmc">PMC10474769</ArticleId><ArticleId IdType="pubmed">37658454</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez-Gonzales W., Chihuantito-Abal L.A., Gamarra-Bustillos C., Morón-Valenzuela J., Zavaleta-Oliver J., Gomez-Livias M., Vargas-Pancorbo L., Auqui-Canchari M.E., Mejía-Zambrano H. Risk Factors Contributing to Reinfection by SARS-CoV-2: A Systematic Review. Adv. Respir. Med. 2023;91:560–570. doi: 10.3390/arm91060041.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/arm91060041</ArticleId><ArticleId IdType="pmc">PMC10740414</ArticleId><ArticleId IdType="pubmed">38131876</ArticleId></ArticleIdList></Reference><Reference><Citation>Conant R.C., Ross Ashby W. Every Good Regulator of a System Must Be a Model of That System †. Int. J. Syst. Sci. 1970;1:89–97. doi: 10.1080/00207727008920220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207727008920220</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>